We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
DATROWAY (AstraZeneca Pty Ltd)
Product name
DATROWAY
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
179 (255 working days)
Active ingredients
datopotamab deruxtecan
Registration type
NCE/NBE
Indication
DATROWAY as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine therapy and at least one additional systemic therapy in the locally advanced or metastatic setting.